Roslin Cell Therapies has launched 'Career Spotlight Series'. The interview with Lucas Colins initiates the series of interviews with key staff members at Roslin Cell Therapies. These will be designed to introduce our staff and share their take on key challenges currently faced by Cell and Gene Therapy sector and thoughts on how to address them.
The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focussed on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary.
Launch of new European Stem Cell Bank EBiSC, the European Bank for induced pluripotent Stem Cells announces the public launch of its on-line catalogue of induced Pluripotent Stem Cells (iPSCs) which are available to academic and commercial scientists for use in disease modelling and other forms of pre-clinical research. (https://cells.ebisc.org).
Edinburgh, Scotland, 28th January 2016 Roslin Cell Sciences, a wholly owned subsidiary of Roslin Cells Ltd, has moved its operations for production of human pluripotent stem cells (iPSCs) for drug discovery to the Roslin BioCentre.
Roslin Cells announces the creation of two commercially focused subsidiaries: Roslin Cell Therapies and Roslin Cell Sciences
Edinburgh, Scotland, 11th January 2016 Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations.
The First Patient In A Clinical Trial Receives Investigational Treatment For 'Wet' Age-Related Macular Degeneration (AMD) Using Retinal Pigment Epithelial (RPE) Cells Manufactured By Roslin Cells
Roslin Cells, a leader in the development and manufacture of cell therapies, confirms today that embryonic stem cell-derived Retinal Pigmented Epithelial cells (RPEs), manufactured for Pfizer Inc., have been used in a recently commenced clinical trial designed to test the safety and efficacy of transplanting the sheet of RPE cells behind the retina of the eye to treat people with ‘wet’ age-related macular degeneration (AMD).
Roslin Cells will work with Tokyo Electron Limited (TEL) and Cell Therapy Catapult, in addition to other partners from academia and industry, to develop standardised Smart Cell Processing Technologies for cell culture and inspection through open innovation. “Our long term goal is to evolve smart cell processing technologies to a fully-automated smart cell factory that can economically and safely produce standardized clinical grade iPS/ES cells” Smart Cell Processing Technologies will comprise hardware solutions in the form of equipment for culture and inspection of cells, as well as software algorithms and characterization methods. This is expected to lead to the generation of a novel system with a shared database and quality management framework to track production processes and ensure and cell quality. TEL will also develop technologies to quantify and standardise cell quality with the National Institute for Biological Standards and Control (NIBSC), as well as stem cell researchers in UK academia.
We share Tokyo Electron’s vision that smart cell processing technology will be essential for the large scale production of cells for therapy and the need for open innovation. Our development programmes will advance faster through collaboration with the STC especially as it is located in the UK,” commented Aidan Courtney, CEO of Roslin Cells.
Roslin Cells announced today that it will be working on a groundbreaking project called “UnTangle” to develop new treatments for dementia. Roslin Cells will manufacture and characterise induced pluripotent stem cell lines (iPSC) which will be used by researchers at UCL and University of Strathclyde to develop new treatments for diseases such as Alzheimer’s. The researchers have already demonstrated that it is possible to use stem cell reprogramming techniques to transform skin cells from a donor into nerve cells which grow connections and communicate with each other. When this is done using cells from Alzheimer’s patients, the nerve cells created in the laboratory develop a build-up of tau protein, similar to that seen in the brains of people with Alzheimer’s and dementia.
Aidan Courtney, CEO of Roslin Cells said, “UnTangle is a great demonstration of how stem cell technology can be used to create cells in the laboratory which have the same disease characteristics as those which cause patients to suffer from a chronic degenerative diseases, such as Alzheimer’s.”
The UnTangle project, which is led by Dr Selina Wray from UCL, has been awarded funding for a 3 year research programme provided by the NC3Rs open innovation platform, CRACK IT. It is in response to the NC3Rs challenge to develop human tissue models which provide a more realistic and reflective model of human disease than using animal experimentation - in support of the aim of NC3Rs to reduce the number of animals required for research.
Edinburgh, Scotland, 21st May 2014 Roslin Cells announced today that it has signed a contract with Pfizer Inc., acting through Neusentis, a research unit of Pfizer based in Cambridge, UK, to support the manufacture of retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial. This trial will evaluate the therapy for the treatment of patients suffering from age related macular degeneration (AMD), the major cause of loss of vision in people aged 65 and older, as part of an ongoing collaboration with The London Project at the Institute of Ophthalmology, UCL.
Roslin Cells Ltd announced today that they will manufacture red blood cells originating from stem cells in their state-of-the art GMP manufacturing facility based at Edinburgh BioQuarter. Manufactured blood will be received by the first human volunteer within the next three years, demonstrating the potential of stem cell technology to produce high quality, plentiful blood supply for use in transfusions.